Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis-Michael Voutsinas, Periklis Panagopoulos, Maria Kosmidou, Vasileios Petrakis, Areti Gravvani, Theologia Gkavogianni, Eleftherios Klouras, Konstantina Katrini, Panagiotis Koufargyris, Iro Rapti, Athanassios Karageorgos, Emmanouil Vrentzos, Christina Damoulari, Vagia Zarkada, Chrysanthi Sidiropoulou, Sofia Artemi, Anastasios Ioannidis, Androniki Papapostolou, Evangelos Michelakis, Maria Georgiopoulou, Dimitra-Melia Myrodia, Panteleimon Tsiamalos, Konstantinos Syrigos, George Chrysos, Thomas Nitsotolis, Haralampos Milionis, Garyphallia Poulakou, Evangelos J. Giamarellos-Bourboulis
Infectious Diseases and Therapy 2021 Dec;10(4):2333-2351
DOI: 10.1007/s40121-021-00505-8
Funding
This work was supported by Abbott Operation Products AG. Funding body had no role in the design, conduct, analysis and interpretation of data and decision to publish. Hughes Associates, Oxford, UK, assisted publication administration, including settlement of the journal’s Rapid Service Fees.
Keywords: COVID-19; Clarithromycin; Th1; Th2; Viral load
Related Study: ACHIEVE